New study tracks how kids with arthritis fare on Long-Term secukinumab
NCT ID NCT07190053
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 22 times
Summary
This study looks at children aged 6 to 17 with certain types of juvenile arthritis (enthesitis-related or psoriatic) who are taking secukinumab. Researchers want to see what treatment strategies doctors use after the child's disease becomes inactive, and how well the drug works over time. About 100 participants will be followed using data from a German registry.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENTHESITIS-RELATED ARTHRITIS (ERA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Conditions
Explore the condition pages connected to this study.